Links for fulltext
     (May Require Subscription)

Article: Survival analysis of high-intensity focused ultrasound therapy vs. transarterial chemoembolization for unresectable hepatocellular carcinomas

TitleSurvival analysis of high-intensity focused ultrasound therapy vs. transarterial chemoembolization for unresectable hepatocellular carcinomas
Authors
KeywordsMorbidity
Liver cancer
HIFU
HCC
Survival
Non-invasive treatment
Mortality
Issue Date2014
PublisherWiley-Blackwell Publishing, Inc. The Journal's web site is located at http://www.wiley.com/bw/journal.asp?ref=1478-3223&site=1
Citation
Liver International, 2014, v. 34 n. 6, p. e136-e143 How to Cite?
AbstractBACKGROUND and AIMS: High-intensity focused ultrasound (HIFU) ablation is a non-invasive treatment for unresectable hepatocellular carcinomas (HCCs), but long-term survival analysis is lacking. This study was to analyse its outcome compared to that of transarterial chemoembolization (TACE). METHODS: From October 2003 to September 2010, 113 patients received HIFU ablation as a treatment of HCCs at our hospital. Twenty-six patients had HCCs sized 3-8 cm. Fifty-two patients with matched tumour characteristics having TACE as primary treatment were selected for comparison. Short-term outcome and long-term survival were analysed. RESULTS: In the HIFU group (n = 26), 46 tumours were ablated. The median age of the patients was 69 (49-84) years. The median tumour size was 4.2 (3-8) cm. In the TACE group (n = 52), the median age of the patients was 67 (44-84) years. The median tumour size was 4.8 (3-8) cm. There was no hospital mortality in any of the groups. In the HIFU group, the rates of complete tumour response, partial tumour response, stable disease and progressive disease were 50%, 7.7%, 25.6% and 7.7% respectively, according to the modified Response Evaluation Criteria in Solid Tumours. The TACE group had the corresponding rates at 0%, 21.2%, 63.5% and 15.4% respectively (P < 0.0001). The 1-year, 3-year and 5-year survival rates were 84.6%, 49.2% and 32.3% respectively, in the HIFU group and 69.2%, 29.8% and 2.3% respectively, in the TACE group (P = 0.001). CONCLUSION: HIFU ablation is a safe and effective method for unresectable HCCs. A survival benefit is observed over sole TACE.
Persistent Identifierhttp://hdl.handle.net/10722/196555
ISSN
2015 Impact Factor: 4.47
2015 SCImago Journal Rankings: 1.677

 

DC FieldValueLanguage
dc.contributor.authorCheung, TT-
dc.contributor.authorPoon, RTP-
dc.contributor.authorJenkins, CR-
dc.contributor.authorChu, FSK-
dc.contributor.authorChok, KSH-
dc.contributor.authorChan, ACY-
dc.contributor.authorTsang, SHY-
dc.contributor.authorDai, WC-
dc.contributor.authorYau, TCC-
dc.contributor.authorChan, SC-
dc.contributor.authorFan, ST-
dc.contributor.authorLo, CM-
dc.date.accessioned2014-04-22T08:34:44Z-
dc.date.available2014-04-22T08:34:44Z-
dc.date.issued2014-
dc.identifier.citationLiver International, 2014, v. 34 n. 6, p. e136-e143-
dc.identifier.issn1478-3223-
dc.identifier.urihttp://hdl.handle.net/10722/196555-
dc.description.abstractBACKGROUND and AIMS: High-intensity focused ultrasound (HIFU) ablation is a non-invasive treatment for unresectable hepatocellular carcinomas (HCCs), but long-term survival analysis is lacking. This study was to analyse its outcome compared to that of transarterial chemoembolization (TACE). METHODS: From October 2003 to September 2010, 113 patients received HIFU ablation as a treatment of HCCs at our hospital. Twenty-six patients had HCCs sized 3-8 cm. Fifty-two patients with matched tumour characteristics having TACE as primary treatment were selected for comparison. Short-term outcome and long-term survival were analysed. RESULTS: In the HIFU group (n = 26), 46 tumours were ablated. The median age of the patients was 69 (49-84) years. The median tumour size was 4.2 (3-8) cm. In the TACE group (n = 52), the median age of the patients was 67 (44-84) years. The median tumour size was 4.8 (3-8) cm. There was no hospital mortality in any of the groups. In the HIFU group, the rates of complete tumour response, partial tumour response, stable disease and progressive disease were 50%, 7.7%, 25.6% and 7.7% respectively, according to the modified Response Evaluation Criteria in Solid Tumours. The TACE group had the corresponding rates at 0%, 21.2%, 63.5% and 15.4% respectively (P < 0.0001). The 1-year, 3-year and 5-year survival rates were 84.6%, 49.2% and 32.3% respectively, in the HIFU group and 69.2%, 29.8% and 2.3% respectively, in the TACE group (P = 0.001). CONCLUSION: HIFU ablation is a safe and effective method for unresectable HCCs. A survival benefit is observed over sole TACE.-
dc.languageeng-
dc.publisherWiley-Blackwell Publishing, Inc. The Journal's web site is located at http://www.wiley.com/bw/journal.asp?ref=1478-3223&site=1-
dc.relation.ispartofLiver International-
dc.subjectMorbidity-
dc.subjectLiver cancer-
dc.subjectHIFU-
dc.subjectHCC-
dc.subjectSurvival-
dc.subjectNon-invasive treatment-
dc.subjectMortality-
dc.titleSurvival analysis of high-intensity focused ultrasound therapy vs. transarterial chemoembolization for unresectable hepatocellular carcinomas-
dc.typeArticle-
dc.identifier.emailCheung, TT: cheung68@hku.hk-
dc.identifier.emailPoon, RTP: poontp@hku.hk-
dc.identifier.emailJenkins, CR: cjenkins@hkucc.hku.hk-
dc.identifier.emailChu, FSK: fchu@hkucc.hku.hk-
dc.identifier.emailChok, KSH: chok6275@hku.hk-
dc.identifier.emailChan, ACY: acchan@hku.hk-
dc.identifier.emailDai, WC: daiwc@hku.hk-
dc.identifier.emailYau, TCC: tyaucc@hku.hk-
dc.identifier.emailChan, SC: chanlsc@hkucc.hku.hk-
dc.identifier.emailFan, ST: stfan@hku.hk-
dc.identifier.emailLo, CM: chungmlo@hkucc.hku.hk-
dc.identifier.authorityPoon, RTP=rp00446-
dc.identifier.authorityJenkins, CR=rp01583-
dc.identifier.authorityChan, ACY=rp00310-
dc.identifier.authorityYau, TCC=rp01466-
dc.identifier.authorityChan, SC=rp01568-
dc.identifier.authorityFan, ST=rp00355-
dc.identifier.authorityLo, CM=rp00412-
dc.identifier.doi10.1111/liv.12474-
dc.identifier.pmid24451026-
dc.identifier.scopuseid_2-s2.0-84902553421-
dc.identifier.hkuros228578-
dc.identifier.volume34-
dc.identifier.issue6-
dc.identifier.spagee136-
dc.identifier.epagee143-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats